Last reviewed · How we verify

Tositumomab and Iodine I 131 Tositumomab

GlaxoSmithKline · Phase 3 active Biologic

Tositumomab and Iodine I 131 Tositumomab is a Monoclonal antibody Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma. Also known as: Bexxar Therapeutic Regimen, anti-B1 Antibody, Iodine I 131 Tositumomab.

Tositumomab is a monoclonal antibody that targets the CD20 antigen on B cells, leading to their destruction.

Tositumomab is a monoclonal antibody that targets the CD20 antigen on B cells, leading to their destruction. Used for Relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma.

At a glance

Generic nameTositumomab and Iodine I 131 Tositumomab
Also known asBexxar Therapeutic Regimen, anti-B1 Antibody, Iodine I 131 Tositumomab
SponsorGlaxoSmithKline
Drug classMonoclonal antibody
TargetCD20
ModalityBiologic
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Tositumomab works by binding to the CD20 antigen on the surface of B cells, marking them for destruction by the immune system. This results in the depletion of B cells, which can be beneficial in treating certain types of cancer. The radioactive iodine (I-131) attached to tositumomab allows for targeted radiation therapy, further enhancing its therapeutic effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Tositumomab and Iodine I 131 Tositumomab

What is Tositumomab and Iodine I 131 Tositumomab?

Tositumomab and Iodine I 131 Tositumomab is a Monoclonal antibody drug developed by GlaxoSmithKline, indicated for Relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma.

How does Tositumomab and Iodine I 131 Tositumomab work?

Tositumomab is a monoclonal antibody that targets the CD20 antigen on B cells, leading to their destruction.

What is Tositumomab and Iodine I 131 Tositumomab used for?

Tositumomab and Iodine I 131 Tositumomab is indicated for Relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma.

Who makes Tositumomab and Iodine I 131 Tositumomab?

Tositumomab and Iodine I 131 Tositumomab is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

Is Tositumomab and Iodine I 131 Tositumomab also known as anything else?

Tositumomab and Iodine I 131 Tositumomab is also known as Bexxar Therapeutic Regimen, anti-B1 Antibody, Iodine I 131 Tositumomab.

What drug class is Tositumomab and Iodine I 131 Tositumomab in?

Tositumomab and Iodine I 131 Tositumomab belongs to the Monoclonal antibody class. See all Monoclonal antibody drugs at /class/monoclonal-antibody.

What development phase is Tositumomab and Iodine I 131 Tositumomab in?

Tositumomab and Iodine I 131 Tositumomab is in Phase 3.

What are the side effects of Tositumomab and Iodine I 131 Tositumomab?

Common side effects of Tositumomab and Iodine I 131 Tositumomab include Myelosuppression, Thyroid dysfunction, Hypersensitivity reactions, Fatigue, Nausea.

What does Tositumomab and Iodine I 131 Tositumomab target?

Tositumomab and Iodine I 131 Tositumomab targets CD20 and is a Monoclonal antibody.

Related